

Jianfeng Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3033489/publications.pdf>

Version: 2024-02-01

243
papers

6,936
citations

117453

34
h-index

91712

69
g-index

259
all docs

259
docs citations

259
times ranked

13541
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. <i>Cell</i> , 2021, 184, 1895-1913.e19.	13.5	512
2	Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. <i>Nature Genetics</i> , 2015, 47, 158-163.	9.4	393
3	Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 137-146.e3.	1.5	374
4	PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. <i>Blood</i> , 2018, 131, 68-83.	0.6	311
5	Identification of functional cooperative mutations of SETD2 in human acute leukemia. <i>Nature Genetics</i> , 2014, 46, 287-293.	9.4	213
6	Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. <i>Cellular and Molecular Immunology</i> , 2020, 17, 992-994.	4.8	202
7	Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. <i>Blood</i> , 2020, 135, 17-27.	0.6	191
8	Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e12-e19.	2.2	176
9	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 69.	6.9	155
10	Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 688-703.	4.2	145
11	Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. <i>Journal of Experimental Medicine</i> , 2010, 207, 505-520.	4.2	137
12	Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. <i>Clinical Cancer Research</i> , 2020, 26, 4216-4224.	3.2	126
13	Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 1237.	1.3	106
14	Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. <i>Leukemia</i> , 2020, 34, 533-542.	3.3	104
15	A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 137, 2890-2901.	0.6	100
16	Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells. <i>Autophagy</i> , 2015, 11, 1849-1863.	4.3	99
17	Precise temporal regulation of Dux is important for embryo development. <i>Cell Research</i> , 2019, 29, 956-959.	5.7	85
18	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 48.	6.9	83

#	ARTICLE	IF	CITATIONS
19	Advances in Universal CAR-T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 744823.	2.2	78
20	Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. <i>Cell Research</i> , 2018, 28, 172-186.	5.7	62
21	5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro. <i>Oncology Reports</i> , 2010, 23, 121-8.	1.2	61
22	Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3999-4006.	0.8	56
23	Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies. <i>Journal of Controlled Release</i> , 2020, 326, 455-467.	4.8	54
24	Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. <i>Gynecologic Oncology</i> , 2007, 106, 299-304.	0.6	53
25	Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. <i>Oncotarget</i> , 2014, 5, 8416-8428.	0.8	50
26	Zinc Finger Nucleases Targeting the Human Papillomavirus <i>E7</i> Oncogene Induce <i>E7</i> Disruption and a Transformed Phenotype in HPV16/18-Positive Cervical Cancer Cells. <i>Clinical Cancer Research</i> , 2014, 20, 6495-6503.	3.2	49
27	Loss of the novel mitochondrial protein FAM210B promotes metastasis via PDK4-dependent metabolic reprogramming. <i>Cell Death and Disease</i> , 2017, 8, e2870-e2870.	2.7	48
28	Tumor necrosis factor α in the onset and progression of leukemia. <i>Experimental Hematology</i> , 2017, 45, 17-26.	0.2	47
29	Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma. , 2019, 7, 315.		47
30	M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion. <i>Blood Advances</i> , 2018, 2, 859-870.	2.5	45
31	Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. , 2019, 7, 271.		45
32	The development and progress of nanomedicine for esophageal cancer diagnosis and treatment. <i>Seminars in Cancer Biology</i> , 2022, 86, 873-885.	4.3	44
33	Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. <i>Blood</i> , 2022, 139, 3148-3158.	0.6	43
34	Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 128.	6.9	41
35	Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 3501.	5.8	40
36	Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5290-5299.	2.5	40

#	ARTICLE	IF	CITATIONS
37	Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. <i>Cancer Letters</i> , 2009, 273, 257-265.	3.2	39
38	MBD2 regulates TH17 differentiation and experimental autoimmune encephalomyelitis by controlling the homeostasis of T-bet/Hlx axis. <i>Journal of Autoimmunity</i> , 2014, 53, 95-104.	3.0	39
39	Mutations or copy number losses of <i>CD58</i> and <i>TP53</i> genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. <i>Oncotarget</i> , 2016, 7, 83294-83307.	0.8	38
40	Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial. <i>Blood</i> , 2018, 132, 148-148.	0.6	37
41	Trichostatin A Targets the Mitochondrial Respiratory Chain, Increasing Mitochondrial Reactive Oxygen Species Production to Trigger Apoptosis in Human Breast Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e91610.	1.1	36
42	Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. <i>Blood</i> , 2022, 139, 3376-3386.	0.6	36
43	A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. <i>Clinical and Translational Medicine</i> , 2021, 11, e346.	1.7	35
44	Loss of <i>Mbd2</i> Protects Mice Against High-Fat Diet-Induced Obesity and Insulin Resistance by Regulating the Homeostasis of Energy Storage and Expenditure. <i>Diabetes</i> , 2016, 65, 3384-3395.	0.3	34
45	<i>PBX3</i> is essential for leukemia stem cell maintenance in <i>MLL</i> -rearranged leukemia. <i>International Journal of Cancer</i> , 2017, 141, 324-335.	2.3	34
46	Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report. <i>BMC Infectious Diseases</i> , 2020, 20, 500.	1.3	34
47	Dynamics of Blood Viral Load Is Strongly Associated with Clinical Outcomes in Coronavirus Disease 2019 (COVID-19) Patients. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 10-18.	1.2	34
48	Transmembrane TNF- α preferentially expressed by leukemia stem cells and blasts is a potent target for antibody therapy. <i>Blood</i> , 2015, 126, 1433-1442.	0.6	33
49	Effects of cryopreservation on chimeric antigen receptor T cell functions. <i>Cryobiology</i> , 2018, 83, 40-47.	0.3	33
50	SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity. , 2020, 8, e000862.		33
51	T Cells Expressing Anti B-Cell Maturation Antigen Chimeric Antigen Receptors for Plasma Cell Malignancies. <i>Blood</i> , 2018, 132, 1013-1013.	0.6	33
52	CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain. <i>Frontiers in Oncology</i> , 2020, 10, 1306.	1.3	32
53	Scoring cytokine storm by the levels of MCP-3 and IL-8 accurately distinguished COVID-19 patients with high mortality. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 292.	7.1	32
54	Novel Oncolytic Adenovirus Selectively Targets Tumor-Associated Polo-Like Kinase 1 and Tumor Cell Viability. <i>Clinical Cancer Research</i> , 2005, 11, 8431-8440.	3.2	31

#	ARTICLE	IF	CITATIONS
55	Circulating CD ¹⁴ ⁺ HLA-DR ^{low} myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease. <i>Cancer Medicine</i> , 2016, 5, 1654-1669.	1.3	30
56	The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis. <i>Cancer Biology and Therapy</i> , 2017, 18, 584-595.	1.5	30
57	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. <i>Current Research in Translational Medicine</i> , 2020, 68, 111-118.	1.2	30
58	Selective Targeting of Checkpoint Kinase 1 in Tumor Cells with a Novel Potent Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2006, 13, 928-937.	3.7	29
59	Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 1789-1800.	2.2	28
60	Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia. <i>Translational Research</i> , 2014, 163, 565-577.	2.2	28
61	Identification of ALPPL2 as a Naive Pluripotent State-Specific Surface Protein Essential for Human Naive Pluripotency Regulation. <i>Cell Reports</i> , 2020, 30, 3917-3931.e5.	2.9	28
62	Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 131.	2.8	28
63	Acid-Responsive Aggregated Gold Nanoparticles for Radiosensitization and Synergistic Chemoradiotherapy in the Treatment of Esophageal Cancer. <i>Small</i> , 2022, 18, e2200115.	5.2	28
64	Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. <i>Cytotherapy</i> , 2020, 22, 166-171.	0.3	27
65	Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 699-707.	1.2	27
66	CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 910.e1-910.e11.	0.6	26
67	T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 85.	7.1	26
68	2-D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2. <i>Biochemical and Biophysical Research Communications</i> , 2019, 513, 1063-1069.	1.0	25
69	The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease. <i>Frontiers in Oncology</i> , 2021, 11, 625872.	1.3	25
70	The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. <i>Molecular Therapy</i> , 2021, 29, 2707-2722.	3.7	25
71	Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. <i>Blood</i> , 2020, 136, 516-519.	0.6	25
72	Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2008, 13, 213-223.	2.2	24

#	ARTICLE	IF	CITATIONS
73	MicroRNA-222 influences migration and invasion through MIA3 in colorectal cancer. <i>Cancer Cell International</i> , 2017, 17, 78.	1.8	24
74	Influence of various medium environment to in vitro human T cell culture. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2018, 54, 559-566.	0.7	24
75	Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy. <i>Blood Cancer Journal</i> , 2021, 11, 168.	2.8	24
76	Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 1147-1156.	3.2	23
77	Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. <i>Cancers</i> , 2022, 14, 3230.	1.7	23
78	Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene. <i>Cancer Letters</i> , 2008, 271, 205-214.	3.2	21
79	Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms. <i>European Journal of Human Genetics</i> , 2021, 29, 1312-1315.	1.4	21
80	Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. <i>Journal of Hematology and Oncology</i> , 2021, 14, 167.	6.9	21
81	Reversal of the Malignant Phenotype of Cervical Cancer CaSki Cells through Adeno-Associated Virus-Mediated Delivery of HPV16 E7 Antisense RNA. <i>Clinical Cancer Research</i> , 2006, 12, 2032-2037.	3.2	20
82	microRNA-222 promotes colorectal cancer cell migration and invasion by targeting MST3. <i>FEBS Open Bio</i> , 2019, 9, 901-913.	1.0	20
83	The utility of non-invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma. <i>British Journal of Haematology</i> , 2020, 189, e45-e48.	1.2	20
84	The effect of RhoA on human umbilical vein endothelial cell migration and angiogenesis in vitro. <i>Oncology Reports</i> , 2006, 15, 1147-52.	1.2	20
85	Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2010, 30, 734-740.	1.0	19
86	Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 333-339.	1.0	19
87	FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 32.	3.5	19
88	Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. <i>EBioMedicine</i> , 2020, 54, 102731.	2.7	19
89	HIF-1 α promotes the migration and invasion of cancer-associated fibroblasts by miR-210. , 2021, 12, 1794.		19
90	A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2021, 27, 5492-5501.	3.2	19

#	ARTICLE	IF	CITATIONS
91	CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies. <i>Blood</i> , 2018, 132, 1408-1408.	0.6	19
92	Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein. <i>Oncotarget</i> , 2015, 6, 3784-3796.	0.8	19
93	Ubiquitin B in Cervical Cancer: Critical for the Maintenance of Cancer Stem-Like Cell Characters. <i>PLoS ONE</i> , 2013, 8, e84457.	1.1	18
94	Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. <i>Frontiers in Immunology</i> , 2021, 12, 755866.	2.2	18
95	Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 824-826.	1.3	17
96	CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2379-2384.	2.0	17
97	Advances in Drug Resistance of Esophageal Cancer: From the Perspective of Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 664816.	1.8	17
98	A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL. <i>Blood Cancer Journal</i> , 2021, 11, 71.	2.8	17
99	Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 4357-68.	1.3	17
100	Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. <i>Oncology Reports</i> , 2005, 14, 275-9.	1.2	17
101	CYC1 Predicts Poor Prognosis in Patients with Breast Cancer. <i>Disease Markers</i> , 2016, 2016, 1-9.	0.6	16
102	Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed/refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 8013-8013.	0.8	16
103	Synergistic defects of UNC13D and AP3B1 leading to adult hemophagocytic lymphohistiocytosis. <i>International Journal of Hematology</i> , 2015, 102, 488-492.	0.7	15
104	MBD2 Ablation Impairs Lymphopoiesis and Impedes Progression and Maintenance of T-ALL. <i>Cancer Research</i> , 2018, 78, 1632-1642.	0.4	15
105	Rheb1 loss leads to increased hematopoietic stem cell proliferation and myeloid-biased differentiation <i>in vivo</i> . <i>Haematologica</i> , 2019, 104, 245-255.	1.7	15
106	Infection complications in febrile chimeric antigen receptor (CAR) T recipients during the peri-CAR T cell treatment period examined using metagenomic next-generation sequencing (mNGS). <i>Cancer Communications</i> , 2022, 42, 476-480.	3.7	15
107	Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 101.	7.1	15
108	Identification of <i>LIV1</i> , a Putative Zinc Transporter Gene Responsible for HDACi-Induced Apoptosis, Using a Functional Gene Screen Approach. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3108-3116.	1.9	14

#	ARTICLE	IF	CITATIONS
109	Rictor/mammalian target of rapamycin 2 regulates the development of notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3. <i>Experimental Hematology</i> , 2014, 42, 1031-1040.e4.	0.2	14
110	Selective bio-labeling and induced apoptosis of hematopoietic cancer cells using dual-functional polyethylenimine-caged platinum nanoclusters. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1465-1470.	1.0	14
111	Determination of Epstein-Barr Virus-Infected Lymphocyte Cell Types in Peripheral Blood Mononuclear Cells as a Valuable Diagnostic Tool in Hematological Diseases. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz171.	0.4	14
112	Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e176.	1.7	14
113	Clinical characteristics of hematological patients concomitant with COVID-19. <i>Cancer Science</i> , 2020, 111, 3379-3385.	1.7	14
114	CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome. , 2020, 8, e000364.		14
115	Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas. <i>Targeted Oncology</i> , 2020, 15, 365-375.	1.7	14
116	Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 846-846.	0.6	14
117	Gut Microbiota for Esophageal Cancer: Role in Carcinogenesis and Clinical Implications. <i>Frontiers in Oncology</i> , 2021, 11, 717242.	1.3	14
118	Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
119	Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells. <i>Cancer Biology and Therapy</i> , 2018, 19, 676-686.	1.5	13
120	Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 21.	7.1	13
121	The Value of Thromboelastography for Bleeding Risk Prediction in Hematologic Diseases. <i>American Journal of the Medical Sciences</i> , 2016, 352, 502-506.	0.4	12
122	A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy. , 2019, 7, 51.		12
123	Serum soluble VSIG4 as a surrogate marker for the diagnosis of lymphoma-associated hemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2020, 189, 72-83.	1.2	12
124	Single-cell transcriptomes of peripheral blood cells indicate and elucidate severity of COVID-19. <i>Science China Life Sciences</i> , 2021, 64, 1634-1644.	2.3	12
125	A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. <i>Frontiers in Oncology</i> , 2021, 11, 750323.	1.3	12
126	Cancer-Associated Fibroblasts Promote the Upregulation of PD-L1 Expression Through Akt Phosphorylation in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 748465.	1.3	12

#	ARTICLE	IF	CITATIONS
127	CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2022, 24, 841-849.	0.3	12
128	A novel "priming-boosting" strategy for immune interventions in cervical cancer. <i>Molecular Immunology</i> , 2015, 64, 295-305.	1.0	11
129	Double-Dose Adenovirus-Mediated Adjuvant Gene Therapy Improves Liver Transplantation Outcomes in Patients with Advanced Hepatocellular Carcinoma. <i>Human Gene Therapy</i> , 2018, 29, 251-258.	1.4	11
130	miR-197 promotes the invasion and migration of colorectal cancer by targeting insulin-like growth factor-binding protein-1/2/3. <i>Oncology Reports</i> , 2018, 40, 2710-2721.	1.2	11
131	Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradation. <i>EBioMedicine</i> , 2019, 40, 92-105.	2.7	11
132	Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder. <i>Frontiers in Oncology</i> , 2021, 11, 709370.	1.3	11
133	Tislezumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study. <i>Blood</i> , 2018, 132, 682-682.	0.6	11
134	Prognostic Value of Geriatric Nutritional Risk Index in Esophageal Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Nutrition</i> , 2022, 9, 831283.	1.6	11
135	Emerging role of nanoparticles in the diagnostic imaging of gastrointestinal cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 580-594.	4.3	11
136	Interdigitating Dendritic Cell Sarcoma: Case Report with Review of the Literature. <i>Onkologie</i> , 2011, 34, 634-637.	1.1	10
137	A Systematic Comparison of the Anti-Tumoural Activity and Toxicity of the Three Adv-TKs. <i>PLoS ONE</i> , 2014, 9, e94050.	1.1	10
138	Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia. <i>PLoS ONE</i> , 2016, 11, e0147545.	1.1	10
139	Search for the potential "second-hit" mechanism underlying the onset of familial hemophagocytic lymphohistiocytosis type 2 by whole-exome sequencing analysis. <i>Translational Research</i> , 2016, 170, 26-39.	2.2	10
140	Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance. <i>Blood Cancer Journal</i> , 2018, 8, 61.	2.8	10
141	Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia. <i>Cancer Medicine</i> , 2020, 9, 4941-4948.	1.3	10
142	Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e198-e205.	0.2	10
143	Upregulation of CD22 by Chidamide promotes CAR T cells functionality. <i>Scientific Reports</i> , 2021, 11, 20637.	1.6	10
144	A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies. <i>British Journal of Haematology</i> , 2022, 198, 62-72.	1.2	10

#	ARTICLE	IF	CITATIONS
145	JAK inhibition as a new treatment strategy for patients with COVID-19. <i>Biochemical Pharmacology</i> , 2022, 202, 115162.	2.0	10
146	TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality. <i>Scientific Reports</i> , 2015, 5, 18454.	1.6	9
147	HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis. <i>Haematologica</i> , 2017, 102, 1956-1968.	1.7	9
148	Disease spectrum of abnormal serum free light chain ratio and its diagnostic significance. <i>Oncotarget</i> , 2017, 8, 82268-82279.	0.8	9
149	Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0158827.	1.1	9
150	Suppression of EphB4 improves the inhibitory effect of mTOR shRNA on the biological behaviors of ovarian cancer cells by down-regulating Akt phosphorylation. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 358-363.	1.0	8
151	Prognosis of Patients With de novo Acute Myeloid Leukemia Resistant to Initial Induction Chemotherapy. <i>American Journal of the Medical Sciences</i> , 2016, 351, 473-479.	0.4	8
152	Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines. <i>Oncology Letters</i> , 2017, 13, 4619-4626.	0.8	8
153	A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T ^h 17 Cells. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	8
154	Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	8
155	TMTP1, a novel tumor-homing peptide, specifically targets hematological malignancies and their metastases. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2011, 31, 608-613.	1.0	7
156	FLT3-ITD-associated gene-expression signatures in NPM1-mutated cytogenetically normal acute myeloid leukemia. <i>International Journal of Hematology</i> , 2012, 96, 234-240.	0.7	7
157	Overexpression of PRDM5 promotes acute myeloid leukemia cell proliferation and migration by activating the JNK pathway. <i>Cancer Medicine</i> , 2019, 8, 3905-3917.	1.3	7
158	AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes. <i>Experimental Hematology</i> , 2017, 45, 36-44.e2.	0.2	6
159	Tumor Microenvironment-Derived R-spondins Enhance Antitumor Immunity to Suppress Tumor Growth and Sensitize for Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2021, 11, 3142-3157.	7.7	6
160	Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study. <i>Journal of Clinical Oncology</i> , 2020, 38, 8034-8034.	0.8	6
161	A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation. <i>Leukemia</i> , 2021, .	3.3	6
162	Chronic myeloid leukemia with variation of translocation at (Ph) [ins (22;9) (q11;q21q34)]: a case report. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13707-10.	0.5	6

#	ARTICLE	IF	CITATIONS
163	A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform. <i>Modern Pathology</i> , 2022, 35, 632-639.	2.9	6
164	A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy. <i>Frontiers in Pharmacology</i> , 2022, 13, 803693.	1.6	6
165	The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK cell lymphoproliferative diseases. <i>Hematological Oncology</i> , 2022, 40, 381-389.	0.8	6
166	The Prognostic Value of D-Dimer in De Novo Acute Myeloid Leukemia. <i>American Journal of the Medical Sciences</i> , 2016, 352, 129-133.	0.4	5
167	The role of thromboelastography in predicting bleeding risk and guiding the administration of platelet transfusions in hematological patients: a cohort study. <i>Annals of Hematology</i> , 2016, 95, 1163-1168.	0.8	5
168	Identification of Significant Pathways Induced by PAX5 Haploinsufficiency Based on Protein-Protein Interaction Networks and Cluster Analysis in Raji Cell Line. <i>BioMed Research International</i> , 2017, 2017, 1-9.	0.9	5
169	Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling. <i>Blood Cancer Journal</i> , 2018, 8, 24.	2.8	5
170	Human MLL-AF9 Overexpression Induces Aberrant Hematopoietic Expansion in Zebrafish. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	5
171	Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 4239-46.	0.5	5
172	Fueling chimeric antigen receptor T cells with cytokines. <i>American Journal of Cancer Research</i> , 2020, 10, 4038-4055.	1.4	5
173	Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1154-1167.	1.5	5
174	PAX5 haploinsufficiency induce cancer cell dormancy in Raji cells. <i>Experimental Cell Research</i> , 2018, 367, 30-36.	1.2	4
175	SLC39A6/ZIP6 is essential for zinc homeostasis and T-cell development in zebrafish. <i>Biochemical and Biophysical Research Communications</i> , 2019, 511, 896-902.	1.0	4
176	Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 567-578.	0.9	4
177	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy. , 2021, 9, e002029.		4
178	Loss of MBD2 attenuates MLL-AF9-driven leukemogenesis by suppressing the leukemic cell cycle via CDKN1C. <i>Oncogenesis</i> , 2021, 10, 79.	2.1	4
179	Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study. <i>Annals of Translational Medicine</i> , 2022, 10, 30-30.	0.7	4
180	T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 873789.	2.2	4

#	ARTICLE	IF	CITATIONS
181	Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model. <i>Cancer Biology and Therapy</i> , 2014, 15, 1153-1162.	1.5	3
182	The LIV-1-GRPEL1 axis adjusts cell fate during anti-mitotic agent-damaged mitosis. <i>EBioMedicine</i> , 2019, 49, 26-39.	2.7	3
183	Loss of MBD2 affects early T cell development by inhibiting the WNT signaling pathway. <i>Experimental Cell Research</i> , 2021, 398, 112400.	1.2	3
184	Clinical Utility of Droplet Digital PCR to Monitor BCR-ABL1 Transcripts of Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Post-chimeric Antigen Receptor19/22 T-Cell Cocktail Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 646499.	1.3	3
185	Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7536-7536.	0.8	3
186	Non-secreting multiple myeloma switches to IgD of lamda type: a case report and review of literature. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 16984-90.	1.3	3
187	Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial. <i>Blood</i> , 2020, 136, 42-43.	0.6	3
188	Autophagy inhibitors enhance biomolecular delivery efficiency of extracellular vesicles. <i>Biochemical and Biophysical Research Communications</i> , 2022, 603, 130-137.	1.0	3
189	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. <i>Frontiers of Medicine</i> , 2021, 15, 783-804.	1.5	3
190	The association of complex genetic background with the prognosis of acute leukemia with ambiguous lineage. <i>Scientific Reports</i> , 2021, 11, 24290.	1.6	3
191	Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies. <i>Hematological Oncology</i> , 2022, 40, 821-834.	0.8	3
192	Cytarabine and paclitaxel exhibit different cell-cycle specificities in different cell growing status. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 416-419.	0.1	2
193	Saline is a more appropriate solution for microvesicles for flow cytometric analyses. <i>Oncotarget</i> , 2017, 8, 34576-34585.	0.8	2
194	Asymptomatic Subclinical Cases of Coronavirus Disease 2019 without Viral Transmission in Three Independent Families. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 3267-3271.	1.1	2
195	Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy. <i>Journal of Cellular Physiology</i> , 2021, 236, 5832-5847.	2.0	2
196	TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy. <i>Diagnostics</i> , 2021, 11, 844.	1.3	2
197	Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL. <i>Blood</i> , 2018, 132, 2054-2054.	0.6	2
198	CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas. <i>Blood</i> , 2020, 136, 11-11.	0.6	2

#	ARTICLE	IF	CITATIONS
199	Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model. <i>Current Pharmaceutical Design</i> , 2015, 21, 1645-1653.	0.9	2
200	The overwhelmingly positive response to Dasatinib of a patient with multiple blast crisis of chronic myeloid leukemia. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 1460-6.	1.3	2
201	Innovative strategies to advance CAR T cell therapy for solid tumors. <i>American Journal of Cancer Research</i> , 2020, 10, 1979-1992.	1.4	2
202	Osteopontin is required for the maintenance of leukemia stem cells in acute myeloid leukemia. <i>Biochemical and Biophysical Research Communications</i> , 2022, 600, 29-34.	1.0	2
203	Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report. <i>Frontiers in Oncology</i> , 2022, 12, 817969.	1.3	2
204	Combination of cytogenetic analysis and molecular screening in patients with de novo acute myeloid leukemia. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 501-510.	1.0	1
205	Establishment of reproducible xenotransplantation model of T cell acute lymphoblastic leukemia in NOD/SCID mice. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 511-516.	1.0	1
206	A single fusion signal for t(14;18)(q32;q21) translocation is present in both the follicular lymphoma and local endothelial cells. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 324-327.	1.0	1
207	Clonal cytogenetic abnormalities are predictor in developing non-Hodgkin lymphomas?. <i>Experimental and Molecular Pathology</i> , 2017, 102, 146-155.	0.9	1
208	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1453-1454.	1.5	1
209	Clinical significance of increased PML-RAR α transcripts after induction therapy for acute promyelocytic leukaemia. <i>Annals of Medicine</i> , 2020, 52, 233-238.	1.5	1
210	Clinical and genetic features of Epstein-Barr virus-triggered late-onset primary hemophagocytic lymphohistiocytosis: Ten pedigrees study. <i>Clinical and Translational Medicine</i> , 2021, 11, e393.	1.7	1
211	Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19507-e19507.	0.8	1
212	Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7533-7533.	0.8	1
213	Droplet Digital PCR Monitoring of TP53 Mutated Circulating Tumor DNA Levels in Lymphoma Patients. <i>Blood</i> , 2018, 132, 4106-4106.	0.6	1
214	Analysis of prognostic factors in lymphoma patients with bone marrow involvement: a single center cohort study. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 9676-83.	1.3	1
215	Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT). <i>Blood</i> , 2021, 138, 94-94.	0.6	1
216	Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. <i>Blood</i> , 2020, 136, 17-17.	0.6	1

#	ARTICLE	IF	CITATIONS
217	Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas. <i>Blood</i> , 2020, 136, 38-38.	0.6	1
218	Molecular mechanism of enhanced apoptotic response in U937 cells mediated by sodium butyrate. <i>Chinese Journal of Oncology</i> , 2002, 24, 320-2.	0.1	1
219	Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1589-1597.	0.6	1
220	Autologous hematopoietic stem cell transplantation in tandem with anti-CD30 CAR T-cell infusion in relapsed/refractory CD30 ⁺ lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7532-7532.	0.8	1
221	Phase I study of the efficacy and safety of IBI319 in patients with advanced malignant tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2646-2646.	0.8	1
222	Ara-C induced apoptosis in human myeloid leukemia cell line HL-60: Inducing apoptosis is the primary mechanism of chemotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 1997, 9, 183-187.	0.7	0
223	Investigation of gene therapy of adenovirus in immune suppression. <i>Frontiers of Medicine in China</i> , 2008, 2, 386-390.	0.1	0
224	Immune safety of a novel oncolytic mutant M1 after administration In Vivo. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 517-523.	1.0	0
225	ZNRF1 can inhibit proliferation and stemness properties of leukemia NB4 cells. <i>Animal Cells and Systems</i> , 2016, 20, 179-185.	0.8	0
226	PAX5 haploinsufficiency induced CD8+ T cells dysfunction or exhaustion by high expression of immune inhibitory-related molecules. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100437.	0.7	0
227	Association of emergence of new mutations in circulating tumor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 845.	1.1	0
228	A Novel Target of Histone Deacetylase Inhibitor, Involves in Mitochondria Membrane Protein Ubiquitination and Regulates Apoptosis.. <i>Blood</i> , 2007, 110, 4187-4187.	0.6	0
229	The Effects of Tcf-1 Gene Silence on Marrow CD4+ T Cells from Aplastic Anemia Patients.. <i>Blood</i> , 2007, 110, 3761-3761.	0.6	0
230	Mobilization, Harvesting and Transplantation of Peripheral Blood Stem Cells in Patients with Severe Refractory Systemic Lupus Erythematosus - A Single Center Experience.. <i>Blood</i> , 2007, 110, 5107-5107.	0.6	0
231	Experiment Therapy of Aplastic Anemia Using Cyclosporin A Combined with IDO Agonist.. <i>Blood</i> , 2007, 110, 1695-1695.	0.6	0
232	Cytotoxic Effects of CML28 Specific T Cells on Acute Leukemia Cells In Vitro.. <i>Blood</i> , 2007, 110, 4886-4886.	0.6	0
233	NOTCH1 Transcriptionally Activates Deptor and Promotes AKT Activation in Acute T-Cell Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 895-895.	0.6	0
234	SHP-1 As a Negative Regulator of FLT3 Associated Aberrant Signaling and a New Potential Target to FLT3-ITD Mutation. <i>Blood</i> , 2018, 132, 4051-4051.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Ikars6 is associated with BCR-ABL1 and myeloid-associated antigens but indicates poor prognosis independently in Chinese adult B-cell acute lymphoblastic leukemia. International Journal of Clinical and Experimental Medicine, 2015, 8, 8497-505.	1.3	0
236	Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma. Blood, 2020, 136, 43-43.	0.6	0
237	Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies. Blood, 2020, 136, 36-37.	0.6	0
238	Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial. Blood, 2020, 136, 4-4.	0.6	0
239	Titelbild: A Reversible Chemogenetic Switch for Chimeric Antigen Receptor Tâ€¦Cells (Angew. Chem.) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	0
240	CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report. OncoTargets and Therapy, 2022, Volume 15, 361-366.	1.0	0
241	PAX5 haploinsufficiency induces low T cell infiltration in the cancer microenvironment via reduced chemokines. Current Molecular Medicine, 2021, 21, .	0.6	0
242	In patients undergoing esophagectomy does postoperative home enteral nutrition have any impact on nutritional status?. Interactive Cardiovascular and Thoracic Surgery, 2022, , .	0.5	0
243	Abstract 2811: CT120, a novel fully human anti-CD19 x anti-CD22 dual targeted chimeric antigen receptor T cell product for the treatment of B-NHL and B-ALL. Cancer Research, 2022, 82, 2811-2811.	0.4	0